-
Join 674 other subscribers
-
Recent Posts
- Board IPR decisions finding conception and reduction to practice before critical date affirmed
- SCOTUS concludes Amgen’s anti-PCSK9 antibody claims not enabled
- Board IPR claim construction (even with harmless error) and obviousness determination affirmed
- DC findings that Vanda’s method of treatment claims are invalid for obviousness affirmed
- IPR obviousness decision reversed as prior art not shown to be analogous to Sanofi’s claimed invention
Recent Comments
Categories
- America Invents Act
- Analgous Art
- Anticipation (35 USC 102)
- Antitrust
- Appeal
- Arbitration
- Article III disputes
- Assignment / Ownership
- Attorney's Fees
- Bankruptcy
- Best mode
- Biosimilars
- Business methods
- Certificate of Correction
- Claim
- Claim Construction
- Claim Differentiation
- Claim Preclusion
- Claim Vitiation
- Collateral estoppel
- comprising
- Conception and Reduction to Practice
- consisting of
- Contributory Infringement
- Copyright
- Covered Business Method Reviews
- Damages
- Derivation of Invention
- Design Patents
- Diligence
- Disclaimers
- Discovery
- Doctrine of equivalents
- Double Patenting
- Enablement
- Equitable estoppel
- Exhaustion and Repair
- Experimental Use
- Expert Testimony
- Extension (156)
- False Marking
- Functional limitations
- Generics / ANDA
- Importation
- Incorporation by Reference
- Indefiniteness
- Inducement to Infringe
- Inequitable Conduct
- Infringement
- Inherency
- Injunction
- Inter Parties Review (IPR)
- Interference
- International Trade Commission
- Intervening Rights
- Inventorship
- IPR
- Issue Preclusion
- Jurisdiction
- Laches
- Licensing
- Lost Profits
- Malpractice
- Markush
- Means-plus-function
- Medical Devices
- Method claims
- Negative Limitations
- Obviousness
- Obviousness (Secondary Considerations)
- Obviousness-Teaching Away
- On-Sale Bar
- Patent Eligibility (101)
- Patent Exhaustion
- Patent Marking
- Patent Prosecution
- Patent Term Adjustment (PTA)
- Patent Term Extension
- Patentability
- Post-grant review
- Preamble
- Priority
- Privilege
- Procedural Issues
- Product-by-Process
- Prosecution History Estoppel
- Public Accessibility
- Public Use
- Ranges
- Reexamination
- Reissue
- Royalties
- Safe Harbor, FDA exemptions (271(e)(1))
- Section 101 (see also Patentability)
- Software
- State Sovereignty
- Summary Judgment
- Terminal Disclaimers
- Trade Dress
- Trade Secret
- Trademarks
- U.S. Supreme Court
- Uncategorized
- Unenforceability
- Unjust enrichment
- Utility
- Venue
- Wherein
- Willfullness
- Written description
Archives
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- July 2011
- February 2011
- January 2011
Meta
- Anticipation (35 USC 102) Appeal Article III disputes Assignment / Ownership Attorney's Fees Claim Construction Claim Differentiation Damages Doctrine of equivalents Enablement Generics / ANDA Indefiniteness Inducement to Infringe Infringement Inter Parties Review (IPR) Inventorship IPR Licensing Means-plus-function Obviousness Obviousness-Teaching Away Patentability Patent Eligibility (101) Prosecution History Estoppel Reexamination Software Trademarks Uncategorized Willfullness Written description
Copyright Notice
© Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com, [2011-2017]. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com with appropriate and specific direction to the original content.
Category Archives: Doctrine of equivalents
DC grant of PI vacated and remanded as Lite-Netics’ infringement allegations not objectively baseless (First Amendment issues relating to customer letters addressed)
Lite-Netics, LLC v. Nu Tsai Capital LLC, Holiday Bright Lights (“HBL”) Docket No. 2023-1146 (h https://cafc.uscourts.gov/opinions-orders/23-1146.OPINION.2-17-2023_2082508.pdf) LOURIE, TARANTO, STARK February 17, 2023 Brief Summary: DC grant of PI vacated and remanded based on the DC’s abuse of discretion in … Continue reading
DC erred in granting SJ of noninfringement as claim construction “dependent on the way the claimed cassette is put to use in an unclaimed structure and erroneous function-way-result analysis
Edgewell Personal Care Brands, LLC et al. v. Munchkin, Inc. Docket No. 2020-1203 (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1203.OPINION.3-9-2021_1745042.pdf) NEWMAN, MOORE, HUGHES March 9, 2021 Brief Summary: DC grant of SJ vacated-in-part, reversed-in-part and remanded (claim construction “dependent on the way the claimed cassette is … Continue reading
DC grant of SJ of infringement to Lilly under DOE affirmed
Eli Lilly And Company v. Apotex, Inc. Docket No. 2020-1328 (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1328.OPINION.12-21-2020_1705369.pdf) PROST, BRYSON, STOLL December 21, 2020 Non-precedential Brief Summary: DC grant of SJ of infringement under DOE affirmed. Summary: Apotex appealed DC grant of Lilly’s motion for summary judgment … Continue reading
DC infringement decision affirmed for one patent, preambles found limiting as to two others, money damages affirmed, injunction for two of four accused products vacated
Bio-Rad Labs., Inc., The Univ. of Chicago v. 10X Genomics Inc. Docket No. 2019-2255, -2285 NEWMAN, O’MALLEY, TARANTO August 3, 2020 Brief Summary: DC decision of infringement of ‘083 patent under DOE affirmed; preamble found to limit ‘407 and ‘193 … Continue reading
DC non-infringement decision affirmed due to disclosure-dedication doctrine
Eagle Pharmaceuticals Inc. v. Slayback Pharma LLC Docket No. 2019-1924 O’MALLEY, REYNA, CHEN May 8, 2020 Brief Summary: DC finding of no infringement under DOE based on disclosure-dedication doctrine affirmed. Summary: Eagle appealed DC judgment of non-infringement of US Pat. … Continue reading
Injunction, damages, infringement and invalidity decisions regarding Illumina’s fetal testing patents affirmed
Verinata Health, Inc., Illumina, Inc. v. Ariosa Diagnostics, Inc., Roche Mol. Sys., Inc. Docket No. 22018-2198, -2303, -2305, -2306, -2317 REYNA, WALLACH, HUGHES April 24, 2020 (Non-precedential) Brief Summary: DC denial of injunction and damages, as well as its refusal … Continue reading
Rejected claim construction proposal during IPR was not prosecution history estoppel, FC affirms infringement under DOE; second infringement decision reversed
Galderma Labs., Nestle Skin Health S.A. et al. v. Amneal Pharm. LLC et al. Docket No. 2019-1021 LOURIE, MOORE, STOLL March 25, 2020 Non-Precedential Brief Summary: DC finding of infringement of certain claims affirmed as statements made in related IPR … Continue reading
DC grant of SJ of no literal or DOE infringement affirmed
Plastic Omnium Advanced Innovation and Research v. Donghee America, Inc. et al. Docket Nos. 2018-2087 NEWMAN, CLEVENGER, REYNA December 3, 2019 Brief Summary: DC grant of SJ of no literal infringement or under the DOE affirmed based on DC claim … Continue reading
Infringement of analyte measurement device claims under DOE barred by prosecution history estoppel
Pharma Tech Solutions, Inc. et al. v. LifeScan, Inc. (Johnson and Johnson) Docket Nos. 2019-1163 MOORE, REYNA, STOLL November 22, 2019 Brief Summary: DC grant of SJ of no infringement under DOE affirmed due to prosecution history estoppel. Summary: Pharma … Continue reading
Lilly’s Orange Book ‘209 patent regarding administration of pemetrexed not literally infringed, but infringed under DOE
Eli Lilly and Company v. Hospira, Inc., Dr. Reddy’s Laboratories Docket No. 2018-2126, -2127, -2128 LOURIE, MOORE, TARANTO August 9, 2019 Brief Summary: DC literal infringement decision reversed, but infringement under DOE affirmed. Summary: Hospira and Dr. Reddy’s (DRL) appealed … Continue reading